Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 12 years of age or older with a minimum body weight of 40 kg~* Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (\>= the following scores: BSA10%, IGA 3, EASI 16, Pruritus NRS 4)~* Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control~Exclusion Criteria:~* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study~* Prior treatment with JAK inhibitors~* Other active nonAD inflammatory skin diseases or conditions affecting skin~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator~* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-04965842 100 mg QD (Type: EXPERIMENTAL): Double-blind randomized treatment following open label run-in period.
- PF-04965842 200 mg QD (Type: EXPERIMENTAL): Double-blind randomized treatment following open label run-in period.
- Placebo QD (Type: PLACEBO_COMPARATOR): Double-blind randomized treatment following open label run-in period.

Based on this trial design, predict the completion outcome and termination type (if applicable).